• Rhythm Pharmaceuticals recently reported preliminary six‑month data from an ongoing Phase 2 trial of setmelanotide in Prader‑Willi syndrome, showing BMI reductions, improved hyperphagia and anxiety scores, and preserved lean mass in 18 patients aged 6–23 years.
• The data, presented at ENDO 2026, highlight setmelanotide’s potential to address both weight and behavioral aspects of PWS while maintaining lean body composition, an important consideration for future Phase 3 planning.
• We’ll now examine how these early PWS results, particularly the improvements in hyperphagia, may influence Rhythm’s existing investment narrative.

Rare earth metals are the new gold rush. Find out which 32 stocks are leading the charge.

Rhythm Pharmaceuticals Investment Narrative Recap

To own Rhythm Pharmaceuticals today, you need to believe that setmelanotide can scale beyond its current rare obesity labels while the company manages ongoing losses and potential dilution. The new Prader Willi Phase 2 data strengthen the case that setmelanotide may address both weight and behavioral symptoms, but they do not change the near term focus on commercial execution in existing indications and the risk tied to Rhythm’s dependence on a single lead asset.

Among recent announcements, the FDA’s March 2026 approval of IMCIVREE for acquired hypothalamic obesity stands out, as it broadens the commercial base that supports Rhythm while PWS and other programs mature. Together with the new PWS data, this expansion underlines how much of the investment case still rests on setmelanotide’s label growth, reimbursement uptake and long term safety profile.

Yet, despite the encouraging trial readout, investors still need to be aware of the risk that Rhythm’s heavy reliance on setmelanotide...

Rhythm Pharmaceuticals' narrative projects $980.6 million revenue and $275.2 million earnings by 2029. This requires 65.3% yearly revenue growth and a $483.0 million earnings increase from -$207.8 million today.

Uncover how Rhythm Pharmaceuticals' forecasts yield a $138.20 fair value, a 54% upside to its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span a wide range, from about US$138 to US$481 per share, highlighting how far apart individual views can be. When you compare that spread with Rhythm’s continuing losses and reliance on setmelanotide as its core asset, it underlines why it can be useful to explore several different viewpoints before forming your own expectations.

Explore 2 other fair value estimates on Rhythm Pharmaceuticals - why the stock might be worth over 5x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Rhythm Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Rhythm Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Rhythm Pharmaceuticals' overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 47 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.